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Candida albicans is a common member of the human gut, skin and mucosal 
microbiomes. Systemic C. albicans infections are of special concern for 
immunocompromised patients such transplant recipients and AIDS patients. Drug 
resistant strains of C. albicans are an enormous health concern and like most antibiotic 
resistant microbes pose a greater risk due to the concomitant acquisition of traits 
associated with pathogenicity. Traditionally microbial control involves antibiotics that 
target specific essential enzymes; however, over the past fifty years there has been an 
exponential increase in resistance of pathogenic bacteria and fungi to known antibiotic 
compounds. Recent developments in electron microscopy have made the study of 
naturally occurring nano and micro-scale hierarchical structures specially on insect 
wings, lotus leaves, shark skin, gecko skin yielding to their super hydrophobic and 
antimicrobial responses. Nanostructured surface (NSS) are attractive alternatives to 
chemical antibiotics because they will not be susceptible to the same pathways towards 
resistance as chemical agonists.  
Recent work has shown that microbes including gram negative bacteria and 
cellular yeast are vulnerable to mechanical assaults via surfaces that exhibit high-aspect 
ratio nanoscale topographies. Though extensive research has been done in mimicking 
naturally occurring NSS and designing new surfaces for antibacterial use, efficacy as 
antifungal agents specially against pathogenic fungi like C. albicans has been ignored. 
The long-term goals of my project are to define the properties of nano structured 
 
 
materials and use these properties for the design and application of novel materials that 
control pathogenic fungal growth and biofilm formation. In this research I have 
characterized the nanoscale mechanical interactions between C. albicans cells and the 
cell-rupturing nanostructured surface from the wing of the Cicada Tibicen ssp; and have 
defined the timing and the conditions that control NSS-induced C. albicans cell rupture. I 
have found that the NSS changes the cell wall composition of this cellular yeast and that 
the NSS induced rupture of this microbe is significantly slower than NSS rupture of 
bacteria on similar surfaces. Different drug resistant strains of C. albicans displayed 
altered responses of rupture and morphogenesis which is attributed to the mechanism of 
drug resistance developed in them.  
Biofilm production which is responsible for the virulence and development of 
resistance in Candida sps. is also significantly reduced when incubated on NSS. Finally, I 
demonstrate data showing Nano-cones on the cicada wing inhibit the transformation of 
yeast to hyphae thus reducing pathogenicity of C. albicans. Following this I used 
synthetic biocompatible NSS as coatings on catheters to determine their antifouling and 
antifungal efficacy in comparison to flat surfaces. This research is extremely necessary 
for a systematic study of microbial interaction with the Nanostructured surfaces and 
define properties to synthesize novel anti-microbial polymers which can be used as 
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1.1  Candida albicans 
Fungi makes up to 7% of the 8.7 million eukaryotic species on earth. Of the 
611,000 species of fungi, only 600 species are reported as human pathogens[1]. The 
infections caused by these commensal pathogens range from the common superficial 
infections of the skin to life threatening systemic infections[2]. Candida albicans (C. 
albicans) is the most prevalent cause of fungal infections in people. Its species name, 
albicans, comes from the Latin word for “white”[3]. C. albicans is an opportunistic 
fungal pathogen commonly found in the mucosal membranes of all humans[4]. It is 
classified as an opportunistic fungus because it usually only causes diseases in those who 
are immunocompromised or whose natural flora have been altered. C. albicans are 
unicellular diploid and are present in the oral cavity of 75% of the population[5].  
C. albicans is a common member of the human gut flora and does not proliferate 
outside the human body. It is detected in the gastrointestinal tract and mouth in 40–60% 
of healthy adults[6]. These opportunistic fungal pathogens cause recalcitrant infections of 
the oral cavity called oral candidiasis. The fungal infection Candidiasis causes conditions 
like Thrush, esophagitis, cutaneous skin candidiasis, vaginal yeast candidiasis, deep 
candidiasis[7]. C. albicans colonizes on skin and mucosal surfaces which can lead to 
acute infections[8, 9]. Though the superficial infections are very common they are often
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non-lethal but in contrast systemic candidiasis is associated with a high crude  
 
mortality[10]. Indeed, Candida species are the fourth most common cause of hospital- 
 






Figure 1.1. Organ/implant related infections caused by C. albicans in Humans 
 
 
An estimate of 75% of all women suffer from vulvovaginitis at least once in their lifetime 
with 40–50% experiencing at least one additional episode of infection[11, 12]. This 
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problem is worse in third world countries where 5–8% suffer from at least four recurrent 
cases of vulvovaginal candidiasis per year mainly because of poor sanitation 
facilities[13]. As a major cause for hospital acquired infections Candida is the root cause 
for 15% of sepsis cases and 40% of bloodstream infections in clinical settings[14]. 
Candida often coexists with other dreadful microbes like Staphylococcus epidermidis and 
Staphylococcus aureus causing serious systemic infections. Candidemia is commonly 
polymicrobial and only a few rare cases of systemic infection of Staphylococcus spp. 
without Candida species were reported[15, 16], which may be due to the need of the 
fungal biofilm for the maintenance of the bacteria infection.      
1.2  Morphogenesis and Pathogenicity of Candida albicans 
C. albicans becomes pathogenic by its ability to transform into different 
morphological forms[17]. They exhibit two prominent proliferation modes the round 
cellular yeast where the cells elongate and bud off yielding daughter cells and the long 
tubular hyphal mode in which continuous lateral growth leads to elongated growth where 
in separate cells are delineated by septa. Most fungi exhibit polymorphism and the 
formation of hyphae and other cellular forms; in fact, the common mushroom fruiting 
body is constructed from collections of hyphae[18]. C. albicans has the ability to 
transform into different morphological forms as a response to the external signals, such as 
nutrient levels/sources, pH, and temperature[19]. Apart from cellular yeast and tubular 
hyphae, different morphologies of C. albicans include an opaque form which is a 
characteristic of mating-competent cells[20], a thick walled spore like chlamydospore 
formed under suboptimal conditions[21] and pseudo hyphae observed as elongated 
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ellipsoid cells with constrictions at the septa[22]. Various environmental conditions affect 
the morphology of C. albicans like low pH (< 6) facilitates the cellular yeast form while 
the higher alkaline conditions promotes hyphal growth[6], nutrient deficient conditions, 
stress induced by the presence of serum, higher incubation temperatures and CO2 induce 
the formation of hyphal structures[23].  
Microbial communication through quorum sensing, play a pivotal role in the 
morphogenesis of yeast[16]. Quorum sensing molecules like farnesol, dodecanol and 
tyrosol affect morphogenesis in C. albicans[24-26]. High cell densities (> 107 cells ml-1) 
have been reported to promote yeast growth, and low cell densities (< 107 cells ml-1) 
favor hyphal formation[27]. Morphogenesis can be induced through phenomena like 
Thigmotropism where cell contact with a surface or galvanotropism where 
morphogenesis is induced by exposure of cells to electric fields[28]. In this dissertation I 
describe a new thigmotropic response of C. albicans. 
The pathogenic behavior of  C. albicans is facilitated by two different  
 
mechanisms: 1)  induced endocytosis by expressing specialized proteins called invasins  
 
on the cells surface and 2) active penetration by the hyphal structures mediated unclear  
 
molecular mechanisms[29]. Invasins mediate binding of fungi to host ligands such as E- 
 
cadherin on epithelial cells and N-cadherin on endothelial cells, ultimately resulting in  
 
engulfment of the fungi into the host cell[30, 31]. The role of hyphal morphogenesis for  
 
the virulence of C. albicans was established from the in vivo experiments in mice[32].    
 
In these experiments,  C. albicans cells carrying the  mutations in two transcription  
 




virulence[33]. Many other genes have been shown to be involved with hyphal  
 
morphogenesis including genes that encode the hyphal wall protein Hwp1, the agglutinin- 
 
like sequence protein Als3, aspartic proteases Sap4, Sap5 and Sap6, and the hypha- 
 
associated proteins Ece1 and Hyr1[34]. 
 
 
   
Figure 1.2.  Common morphologies of pathogenic fungi C. albicans (a) 
Oval/spherical C. albicans yeast. (b) Tubular C. albicans hyphae 
 
 
1.3 Candida Detection and Diagnosis 
Poor diagnosis of fungal disease around the world resulting in over prescription of  
antibiotics and increasing harmful resistance to antimicrobial drugs. C. albicans can be 
identified by simple methods such as germ tube or colorimetric test or by using selective 
chromogenic agar tests[35]. Conventional C. albicans detection methods based on 
phenotype include microscopic examination, blood culture, and biochemical 
identification[36]. However, they are time-consuming, labor-intensive with low 
sensitivity. The long period of waiting time required to diagnose C. albicans infection 
often leads to a delay in the start of treatment with antifungal drugs. Additionally, several 
molecular biological methods have been applied to the detection of C. albicans, such as 
Polymerase Chain Reaction (PCR)[37], Real-Time PCR(RT-PCR), mass 
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spectrometry[38], and immunoassay[39]. Though there are no FDA approved PCR assays 
to detect C. albicans both commercial and inhouse PCR tests are widely used on serum or 
whole blood samples for detection. Definitive identification of the pathogenic fungi can 
be achieved by automated systems such as API Candida (bioMerieux), the MicroScan 
WalkAway System (Dade Behring), Vitek (bioMerieux), Auxacolor (Sanofi Diagnostic 
Pasteur), or Yeast Star (CLARC Laboratories) but these commercial techniques are often 
expensive and are limited by their prolonged time to obtain final results, averaging 24 to 
48 hours[40, 41]. Despite considerable advances for candidiasis detection, the 
development of simple, compact and portable point-of-care diagnostics for rapid and 
precise testing that automatically performs cell lysis, nucleic acid extraction, purification 
and detection still remains a challenge. 
1.4 Candida Biofilms 
Most microorganisms in their natural habitats are attached to surfaces within a 
structured biofilm ecosystem rather than existing as free-floating planktonic 
organisms[42]. Biofilms are structured microbial communities attached to surfaces and 
encapsulated within a protective extracellular matrix. Biofilms are produced by both 
motile and non-motile organisms. Study of biofilms is gaining importance because a 
majority (65%) of all human microbial infections are biofilm based[43] and surprisingly 
more (80%) of the microbial infections in the United States are biofilm based[44].  
Biofilms are complex communities of cells that are attached to a substrate and 
themselves by means of an organic glue-like substance known as the Extracellular 
Polymeric Substance (EPS)[45]. The EPS performs the important structural role of 
7 
 
stabilizing the cells and provides a protective environment against mechanical damage 
and shear caused by fluid flow at the interface[46-48]. The EPS is a  complex matrix that 
is composed of polysaccharides, proteins, and extracellular DNA that is secreted by the 
members of the biofilm community by processing the nutrients available upon adhesion 
to the substrate[49]. The EPS allows its community members to share nutrients, 
communicate through chemical signaling molecules (i.e. quorum sensing), pass along 
genetic information through lateral gene transfer, and are even involved in promoting 
electron transfer[50]. All these functions are enhanced in biofilm communities compared 
to planktonic cells and increase antifungal drug resistance up to 1000-fold[51]. Indeed, 
the inefficacy of antifungal therapy against different fungal biofilms have been shown 
and stated by several studies[52-54].  
 A significant attribute in virulence of  C. albicans is the formation of three-
dimensional biofilm on biotic surfaces and abiotic surfaces like dental enamel, catheters 
and other biomaterial implants[55]. Formation of biofilms by Candida species occur in a 
systematic manner; cellular fungi attach to the substrates and grow horizontally to form a 
basal layer then hyphal cells are produced on the upper layers and with further secretion, 
biofilms are usually covered with extra cellular matrix [56, 57]. Adherence of fungal cells 
to biomaterial surfaces must first occur for colonization to take place[58]. The initial 
attachment of Candida cells to biomaterials is mediated by both nonspecific factors (cell 
surface hydrophobicity and electrostatic forces) and by specific adhesins on the fungal 
surface recognizing ligands in the conditioning films, such as serum proteins (fibrinogen 
and fibronectin) and salivary factors[59]. 
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C. albicans biofilm formation has four developmental phases [Figure 1.3][60]:  
i. Early phase - adherence of yeast cells to the device surface 
ii. Intermediate phase - formation of a matrix with dimorphic switching 
from yeast to hyphal forms 
iii. Maturation phase - increase in the matrix material taking on a three-
dimensional architecture 
iv. Dispersion – involves release or translocation of individual cells or  
 




Figure 1.3. Stages of Biofilm formation[60] 
 
 
Fully mature Candida biofilms have a mixture of morphological forms and 
consist of a dense network of yeasts, hyphae, and pseudo-hyphae in a matrix of 
polysaccharides, carbohydrate, protein, and unknown components[61]. The formation 
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and structure of C. albicans and Candida species biofilms is influenced by the nature of 
the contact surface, environmental factors, morphogenesis, and the species involved[60]. 
Though biofilms formation encourages the morphogenesis of yeast to hyphae all fungal 
morphologies indefinitely have the ability to form biofilms this was confirmed by testing 
the biofilm formation efficacy of hyphal gene knockouts of C. albicans[62]. Several 
transcription factors including Efg1p, Cph1p, Efh1p, Rap1p, Ino4p, and Tec1p have been 
shown to be essential for biofilm formation[57, 63]. Quorum sensing based cell-cell 
communication maintains biofilm by preventing unnecessary cell proliferation and 
controlling competition for nutrients[64].  This has important implications in the 
infectious process, particularly for dispersion of cells from the mature biofilm and the 
establishment of distal, secondary infections. It has been shown that farnesol acts as a 
quorum-sensing molecule that inhibits filamentation in C. albicans[24].  
1.5 Candida Biofilms on Biomaterial Implants 
Biofilms associated with C. albicans and other Candida species cause a variety of 
infections on implantable medical devices. Removal of these implants is required to 
eliminate the infection caused by irreversible adhesion of biofilms to these surfaces. 
Removal of implanted material is a painful process and might not even be often possible 
due to its anatomical location or state of infection. The implanted material might be 
attacked by the fungi either during contaminated administering conditions or from inside 
the body. As these surfaces are often surrounded by body fluids such as urine, blood, 
saliva and synovial fluid, their surfaces tend to acquire a glycol-proteinaceous 
conditioning film, which changes the original surface chemistry of the surface and 
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facilitates microbial adhesion[65]. The most important characteristic of biofilms 
produced by C. albicans and Candida species  is resistance to conventional antifungal 
therapies[51, 62, 66, 67]. Intrinsic resistance of the biofilms can be caused by (a) biofilm 
matrix blocking the penetration of drugs (b) morphogenesis due to nutrient limitations (c) 
expression of efflux pump resistance genes and (d) presence of persister cells[68-70]. 
Implantable devices such as shunts, prostheses (voice, heart valve, knee, etc.), 
 
stents, implants (lens, breast, denture.), endotracheal tubes, pacemakers and various types  
 
of catheter support colonization and biofilm formation by C. albicans and Candida  
 
species (Table 1). Not only does Candida colonization of biomaterials precede infection,  
 
but it can also adversely affect the function of the implanted device. C. albicans and  
 
Candida species are the third leading cause of intra vascular catheter infections with a  
 
very high mortality rate[71]. These fungi are responsible for most catheter-related urinary  
 
tract infection, which remains a leading cause of nosocomial infections, with significant  
 
morbidity, and additional hospital costs[72, 73]. C. albicans and other Candida species  
 
are now the microbial pathogens that are most frequently isolated from the urine samples  
 
of patients in surgical intensive care units (ICUs), with about 10–15% of nosocomial  
 
urinary tract infections being caused by Candida species[74]. While most catheters are  
 
made of silicone research has shown that C. albicans and Candida species adhering to  
 
silicone displayed enhanced tolerance to fluconazole and is related to efflux pump[75].  
 
Treating implant associated fungal infections typically requires surgical procedures to  
 
remove all infectious materials and necrotic tissue which may also involve the implant  
 




infections and resistance in Candida species research pertaining to the study of alternate  
 
approaches to existing fungal drugs is necessary and, in this research, I study the anti- 
 
fouling and antimicrobial efficacy of nanostructured surfaces.  
 
 
Table 1.1. Risk of infections caused on medical implants in the human body by 
Candida species 
 

















240,000 1-20% C. albicans 
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40,000 6-15% C. albicans [84] 











1.6 Bacterial-Fungal Interactions in Infections 
One of the most widely studied microbial interplays is the bacterial-fungal 
interaction[87, 88]. Many complicated infections are an interplay between two pathogens 
and often are found in patients with intravenous catheters, cystic fibrosis patients, the 
respiratory tract of ventilated patients, and burn wounds[89]. The current antibiotic drugs 
often target single species of microbes and harsh multi-microbial targeting drugs often 
have complications and side effects making these complicated infections challenging to 
treat. Most of these polymicrobial interactions are mediated by mechanisms that also 
serve as virulence factors, including quorum sensing, biofilm formation, production of 
secondary metabolites, and cellular signal transduction[90-92]. Bacterial-Fungal 
interactions are initiated by mutual support of their growth but potentially lead to 
suppression of one organism and dominant growth of another, based on the 
microenvironment of the host. Several studies have demonstrated that polymicrobial 
infections can be more severe and result in considerably higher mortality than infections 
with single pathogens[93, 94]. P. aeruginosa produces phenazines/pyocyanin , decanol, 
and 3-oxo-C12-homoserine lactone (3OC12HSL), which inhibit C. albicans biofilm 
formation and hyphal development.  These bacterial analytes induce the formation of 
reactive oxygen species (ROS) and increase the virulence of C. albicans by producing the 
proteolytic enzyme elastase (LasB)[95, 96]. The strong adherence and synergistic 
interaction between different C. albicans with pathogenic bacterial (e.g. Actinomyces spp, 
Lactobacillus spp, Staphylococcus spp) promotes stable, mature biofilms and enhanced 
colonization at multiple sites in the human body[91, 97, 98]. 
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1.7 Antimicrobial Resistance 
Traditionally the control of microbes has been done with chemical antibiotics, 
compounds that target specific essential enzymes; however, over the past fifty years there 
has been an exponential increase in resistance of pathogenic bacteria and fungi to known 
antibiotic compounds. Antibiotic resistance is a global threat to public health[99, 100]. 
Continued misuse of antibiotics runs parallel to the swift evolution of multi resistant 
microbial pathogens, which has led to an enormous rise of therapy resistant diseases. This 
behavior has resulted in the ineffectiveness of conventional therapies. At the 
cellular/molecular levels anti-drug resistance is manifested by the emergence of genetic 
alterations that either directly interfere with the binding of the drug to its cellular target, 
or by inducing gene expression that reduces drug susceptibility[101]. Antibiotic 
resistance  issue is a serious concern in post-operative patients like implant recipients due 
to colonization of resistant pathogenic species at the transplant-tissue interface[102-104].  
Inaccurate diagnosis of fungal sepsis in hospitals and intensive care units results 
in inappropriate use of broad-spectrum antibacterial drugs in patients with invasive 
candidiasis, fungal infections caused by yeasts. Different drugs and methods have been 
studied to control and kill the pathogenic fungi C. albicans and its biofilm. Despite the 
clinical and economic relevance of drug resistance in the context of yeast infections, this  
subject remains poorly studied, at least in comparison with the similar issue of antibiotic 





1.8 Anti-fungal Approaches and Resistance 
In comparison to anti-bacterial research antifungal research has made very little 
progress. This is somewhat justified by the low occurrence of fungal infections, but 
recent  increase in fungal infections by both planktonic and biofilm associated fungal 
infections has put us in jeopardy. Resistance to currently available fungal drugs and rising 
fatalities caused due to the coexisting bacterial and fungal species, aggressive research on 
new antifungal agents is becoming a priority[105]. Fungi are eukaryotic, with a closer 
evolutionary relationship with human hosts regarding basic cellular and molecular 
processes.  These similarities lead to slow development/discovery of antifungal drugs, 
which complicates the process[106]. Nonetheless, detailed knowledge regarding the 
structure, composition and biochemistry of fungal cells has contributed to our 
understanding about the mechanism of action of many antifungal agents[107].  
The fungal cell wall, which gives the cell a definitive structure and serves as a 
sensory interface with the external environment, is composed of chitin, glucans, 
mannans, and glycoproteins.  The fungal cell wall is essential for adhesion and fungal 
pathogenesis and also acts as a protective barrier limiting the access of molecules to the 
plasma membrane[108]. The main antifungal drugs target the cell wall, specifically 
compounds that inhibit biosynthesis of chitin and β-glucan synthesis[109]. Chitin a β-1-
4-linked N-acetylglucosamine polymer an essential component of fungal cell wall 
constitutes to a very small amount (1-2%) in cellular yeast but in considerable quantity in 
filamentous fungi (10-20%) and plays a key role in providing rigidity, structural support 
and maintains structural integrity of the thin fungal cells. 
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C. albicans during colonization or infection must adapt to environmental changes 
 
in the host. The C. albicans cell responds to these environmental challenges by altering  
 
the expression of specific genes, thereby altering specific biochemical synthetic  
 
pathways[110, 111]. These acute/ rapid responses will lead to more permanent alterations  
 
to the genome. Selection of adaptive mutations and the evolution of genetically altered  
 
variants of C. albicans that have adapted to the host's niche initiates conditions that lead  
 
to drug resistance[112-114]. Patients infected with C. albicans are treated with antifungal  
 
drugs, that are either systemic or topical based on their mode of introduction. 
 
 
Table 1.2. Classification of commonly used antifungal drugs and their mode of 
action. 
 

















Binding to ergosterol 
Pyrimidine analogue Flucytosine 








Antifungal drugs are classified into three types (a) Azoles (b) Echinocandins and 
 
(c) Polyenes (table 1.2). Systemic drugs include flucytosine, Imidazoles, Triazoles,  
 
Haloprongin, Tolnaftate are examples of topical drugs. Mechanism of antifungal is  
 
mainly by inhibiting fungal cell wall and membrane biosynthesis and by alteration of  
 
microtubules or by inhibition of nucleic acid synthesis. Systemic antifungals like  
 
amphotericin B are toxic to mammalian cells. Most anti-fungal drugs currently available  
 




Figure 1.4. Targets of commonly used antifungal candidates [115] 
 
 
Fluconazole is an example of commonly used anti-fungal drug and works by  
 
inhibiting biosynthesis of ergosterol, a key component of the fungal cell membrane. The  
 
drug targets 14α-demethylase encoded by ERG11 and mutation caused in it will result in  
 
amino acid exchanges that reduce affinity of enzyme for the drug[116]. Another  
 




component of fungal cell wall biosynthesis and mutations in FKS1 result in reduced drug  
 
binding[117]. In addition to anti-fungal drug used in therapeutic treatment, C. albicans  
 
encounters many innate antimicrobial agents taken up or generated by host. Saliva  
 
secreted in the oral cavity contains antimicrobial peptides including histatin 5 which is  
 
not membrane lytic but acts intracellularly to cause cell death[118]. Extracellular glycol- 
 
domain of the plasma membrane protein Msb2 of C. albicans is released into the  
 
environment which binds to Hst5 and other antimicrobial peptides evading the hosts  
 
antimicrobial response[119]. With increasing resistance in fungi towards the available  
 
antifungal drugs need for newer drugs and alternative methods for fungal infections needs  
 




Figure 1.5. Antifungal drug actions and resistance mechanisms in Candida (A) 
Action mechanisms of drugs in different parts of the cells. (B) Common resistance 
mechanisms developed in C. albicans to antifungal drugs[120]. 
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Commonly used drugs like caspofungin, micafungin, and anidulafungin of class 
Echinocandins act on mechanisms specific to fungal cell wall. Echinocandins target the 
protein complex responsible for the synthesis of β-1,3 glucans by blocking the enzyme 
glucan synthase[121]. This results in the decrease in the incorporation of glucose 
monomers linking β-1,3 and β-1,6 glucans, thereby weakening the cell wall and leading 
to fungal cell lysis[106, 122]. 
1.9 Antimicrobial Surfaces 
In general, there are two ways to stop microbes from infecting humans or 
deteriorating materials: disinfection and antimicrobial surfaces. Many innovative 
technologies have been developed to impart antimicrobial function or activity to 
biomedical materials to prevent or treat infection and biofilm development[123], though 
most of these technologies are designed for controlling bacterial biofilm formation, 
Antimicrobial surfaces may be classified as anti-adhesive or bactericidal depending on 
the nature of the antimicrobial activity[124]. According to Munoz-Bonilla and 
Fernandez-Garcia (2012) the polymeric materials with antimicrobial activity can be 
classified as follows:  
i. Polymers that exhibit inherent antimicrobial activity 
ii. Polymers whose biocidal activity is conferred through chemical surface 
modification 
iii. Those that incorporate antimicrobial organic compounds with either low or 
high molecular weight; and  








1.9.1 Antifouling or Anti-Adhesive Surfaces 
The first step for any microbial infection in adhesion and there is no possibility of 
microbial colonization if adhesion can be prevented. Microbes adhere to surfaces by 
physio-chemical surface interactions or species-specific active mechanisms mediated by 
adhesins[126, 127]. These can be structurally quite simple coatings, such as hydrogels, or 
involve more complex architectures, such as polymer brushes. Several studies have also 
investigated the use of such “antifouling” or “anti-adhesive” coatings to prevent 
attachment and biofilm formation by fungal organisms. A polymer brush layer formed by 
covalently attaching poly(ethylene oxide) polymers to glass surfaces decreased the 
growth of C. albicans by 70% compared to uncoated glass surfaces[128]. Acrylic plates 
coated with carrageenan and hydrocolloid were challenged with 27 isolates from Candida  
spp. and a decrease in adhesion of hydrophobic hyphal Candida spp., without affecting 





1.9.2 Intrinsically Anti-Microbial Bioactive Materials 
Bulk materials that exert an antimicrobial action in the absence of modifications, 
such as loading with antibiotic substances or coating with active functional molecules, 
can generally be described as intrinsically antimicrobial. Silver has been described as one 
of the earliest materials used in surgery for its antimicrobial properties. Numerous 
substances are known to possess bactericidal and fungicidal properties, among them 
several metals, such as silver[130, 131], zinc[132] and copper, some polymeric materials, 
such as chitosan and its potentiated derivatives, and various bioactive glasses. Candida 
sps being complex eukaryotes sharing similar cellular ingredients as host, the cytotoxicity 
of the materials needs to be highly specific or can potentially affect the host cell/tissue. A 
detrimental effect can be determined even when the materials interact with host cells 
causing a loss of cell differentiation at the interface with the implant. Chitosan is a 
polycationic polymer derived from chitin and has been broadly used as a stable 
antimicrobial biomaterial platform with other biocidal organic and inorganic 
compounds[133-137].  
1.9.3 Drug Releasing Surfaces 
Drug-releasing biomaterials enable delivery of drugs that are otherwise inefficient 
or even impossible to deliver systemically. Anidulafungin, an approved antifungal drug, 
is one of those drugs, but its hydrophobic nature requires intravenous administration. To 
address this, surfaces coated with cyclodextrins[138], chlorhexidine and 
chloroxylenol[139], chloroxylenol, thymol[140], along with commercial antifungal drugs 
have demonstrated a significant lower adhesion or reduced infections by Candida sps. 
21 
 
Drug release from bulk materials, thin film coatings, hydrogels and grafted polymers is 
being widely researched for use mainly as coatings on medical implants[141]. 
1.9.4 Contact Killing Surfaces 
Antimicrobial releasing coatings deplete over a period of time, can produce non-
specific response in the host and sustained low-level tail-release will contribute to the 
development of antibiotic-resistance[142]. Contact killing surfaces can solve the problem 
for long-term antimicrobial activity[143-146]. The combination of contact killing and 
non-adherent properties in surfaces is used to inhibit the deposition of biomolecules like 
proteins, serum and other body fluids[147]. Efficacy of contact-killing quaternary 
ammonium-coated surfaces has been demonstrated over a time period of several days by 
in-vivo experiments[148]. 
1.9.5 Nanostructured Antimicrobial Surfaces 
Nanostructured surfaces occur abundantly in nature, from the superhydrophobic 
surfaces of lotus leaf which provide anti-adhesive quality to the various cuticular 
structures of different insects with anti-wetting, anti-drag and even optical 
properties[149]. These nano-architectures impart multi-functionality, affording a broad 
spectrum of favorable properties, often including the ability to self-clean[150], exhibit 
super hydrophobicity[151], and possess antibiofouling properties. Common examples of 
surfaces that exhibit combinations of these behaviors include: insect wings, such as those 
of cicadae[152-155], damselflies[156] and dragonflies[157, 158], shark skin[159-161], 




occurring bactericidal surfaces are useful in providing a starting point in the design of 
antimicrobial structures[166]. 
Research on the impact of surface topography on microbial adhesion has been 
conducted since the last three decades but definite evidence on how these topographies 
modulate colonization is lacking[167-170]. Since most of these biofilms associated 
organisms exist on the micron scale, their attachment behavior on surfaces is also studied 
on micro and nanoscale topographies. Though the influence of surface topography and 
roughness of bacterial attachment has been recently studied, the interaction of a much 
complex fungal system has not been given great deal of attention. The conventional 
theories state that smooth surfaces render a repellent environment to the bacteria whereas 
rougher surfaces facilitate adhesion by providing more adhesion points[171, 172]. 
Contradictory to these, cells exhibited greater propensity for adhesion on the nano-
smooth surfaces due to the production of extracellular polymeric substances (EPS)[173]. 
Periodic nanoscale arrays of high aspect ratio polymer posts have been reported to direct 
the attachment behavior of P. aeruginosa, B. subtilis and E. coli cells[174]. Cell adhesion 
on superhydrophobic surfaces are studied in an effort to create surfaces to reduce 
microbial colonization[175]. The rationale for this is that the air trapped between the 
dual-scale surface features present on such surfaces limits the available contact area for 
the bacteria[176]. Depressions with diameters of 2.5 μm etched into the surface of optical 











Preliminary research on C. albicans response to rough surfaces showed that the  
 
pathogenic yeast attached to scratch marks and pits were created by scratching with  
 
emery paper[178].  But C. albicans did not show any significant change in adhesion on  
 
surface pits in the size range 0.2–2 μm[179]. Recent research on Candida adhesion on  
 
patterned 120nm diameter pits showed decrease in adhesion compared to flat solid[180].  
 
Adhesion of cellular C. albicans was demonstrated to be significantly higher on  
 
TiO2 coatings when compared to TiO2 nanoparticles[181, 182]. Understanding the  
 
mechanism and parameters for these antimicrobial surfaces will allow manufacturers to  
 






biofilms, or even allow the synthesis of a surface that has the capacity to kill any  
 
microbes that come into direct contact. 
 
1.10 Antimicrobial Efficacy and Nanostructured Topography of Cicada Wing 
Natural superhydrophobic surfaces are often thought to have antibiofouling 
potential due to their self-cleaning properties, but the wings of Cicadas ruptured the 
Pseudomonas aeruginosa and have demonstrated to have anti-microbial properties as 
opposed to antibiofouling nature. Extensive research in electron microscopy techniques 
helped us analyze the structural topology of the natural available surfaces with innate 
anti-microbial super hydrophobic properties to create structured surfaces with similar 
properties by reverse engineering. Researchers have identified nano cone structures on 
the dorsal and ventral wing membrane sections of the Cicada wing and later confirmed 
their anti-bacterial efficacy[149, 151, 152]. Detailed AFM and SEM studies on the wings 
of Cicada sps (Tibicen tibicen) confirmed the presence of arrays consisting of 
hexagonally-packed spherically-capped conical protuberances with a spacing and height 
of 200 nm and radius of curvature of 35–55 nm at the apex. The nano structuring of 
surfaces with an ordered array of features increases the hydrophobicity as described by 
the Cassie and Wenzel models[175]. Sun et al., have systematically investigated both the 
wetting and optical properties of different cicada species as a function of their structure; 
also, the height, diameter and spacing of the nanopillars varies between cicada 
species[183, 184]. The natural surfaces of insect wings have been studied to exhibit 
complex chemical compositions of chitin, proteins, polyphenols and wax[185, 186]. The 
superhydrophobic nature of the Cicada wing is attributed to the sophisticated nano 
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structured topography and also the presence of wax yielding to a decreased 
wettability[187]. 
The first study on mechanical inhibition of bacteria by native nanostructure of  
 
cicada wing demonstrated a reduced cell numbers in a suspension of Pseudomonas  
 
aeruginosa by almost half within one hour, with a single cell being able to be ruptured in  
 
approximately 4 minutes. Cicada wings exhibited general bactericidal activity against  
 
Gram- negative cells, regardless of their morphology, while Gram-positive cells were  
 
found to be resistant to the antibacterial nature of the wing[152]. Mathematical models of  
 
bacterial interaction with cicada wings demonstrated the rupture of bacterial cells is due  
 
to the stretching of cell membranes suspended between the nano cones[188]. Gram- 
 
positive cells have a greater natural resistance to this effect than do Gram-negative cells,  
 
due to their greater rigidity. Nowlin et al experimentally demonstrates that there is a  
 
relationship between cell rupture/death of Saccharomyces cerevisiae  and the  
 
nanostructure geometry of NSS[189]. 
 
 
   
Figure 1.7. Scanning Electron Microscope image of Nanostructured surface 
of the Cicada wing (a)Cicada bug Tibicen tibicen (b)Scanning electron microscope 





SYSTEMATIC STUDY OF MECHANISM OF CANDIDA ALBICANS   RUPTURE 
 




Candida albicans is a unicellular, diploid fungi that is a common member of the 
human commensal microbiome of the gut, skin and mucosal membranes[190].  While C. 
albicans is found in all healthy humans, in certain circumstances this microbe is 
responsible for a variety of diseases from the common oral thrush to life threatening 
systemic infections[191].  C. albicans, unlike a few other Candida species, lack the 
ability to proliferate outside the human body and therefore pose a unique threat and 
problem to human health[192].  C. albicans infection is a serious problem mainly in 
immunodeficient patients particularly implant recipients, patients suffering from HIV 
where it causes conditions like Candidiasis and invasive Candidiasis which might lead to 
fungal sepsis[6]. Candida related medical issues are mainly because of its ability to form 
biofilms. Mature Candida biofilms host a mixture of morphological forms of the C. 
albicans including cellular, hyphal, and pseudo hyphal forms that are embedded in a 
complex polysaccharide matrix that attracts a community of  pathogenic and non-
pathogenic bacteria and other fungi[193]. The structure and composition of the Candida 
biofilm depends on the nature of contact surface, environmental factors, morphogenesis 
and the species involved[61]. C. albicans cells within the biofilm exhibit phenotypic
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resistance to antimicrobials and host defense which might lead to reinfection[194]. 
Candida biofilms also host pathogenic microorganisms like Methicillin-resistant 
Staphylococcus aureus, which cause infection on indwelling medical devices like 
catheters, ocular lenses, cardiac valves and shunts[55, 195, 196]. The need for novel 
approaches for antifungal treatment and therapies is dire. Although antifungal drugs such 
as azoles (i.e. fluconazole and voriconazole), echinocandins (i.e. caspofungin and 
anidulafungin), and others (i.e. flucytosine and amphotericin B) have been critical for 
combating fungal infection, the prevention of these Candida infections is becoming 
problematic with the increase in antifungal drug resistance and the emergence of  
“superbugs” [197].  The increased misuse of antibiotics, pesticides and continued 
evolution of multi-drug resistant microbial pathogens cumulatively add to the growing 
resistance in microbes and the failure of existing antibiotics[198]. 
Candida associated biofilm infections have been reported to affect around 10% of 
the medical implant recipients in the US alone and lead to nearly 100,000 deaths per 
year[4]. Implant associated C. albicans infections after breast augmentation ranged from 
1.1% to 2.5%[199] and C. albicans infections associated with breast reconstruction after 
mastectomy ranged from 1%-35%[200]. Unlike a few other Candida sps C. albicans lack 
the ability to proliferate outside the human body[192]. C. albicans and related yeast 
species are pathogenic mainly by their ability to exist in different morphological forms 
like the cellular yeast and tubular hyphal states. In particular,  hyphal fungal cells have a 
special ability to produce proteins that protects and mask them from host immune 
oxidative stress responses and enable the fungus to evade phagocytosis, escape the 
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bloodstream and colonize on the organs/implants form biofilms and lead to failure[201]. 
Antimicrobial surfaces are a relatively new class of antimicrobial approaches 
which involve the application of inherently antimicrobial materials and surface coatings. 
Nanostructured antimicrobial surfaces have been proposed as a stand-alone treatment or 
as a potential addictive treatment with existing antimicrobial agents[202]. One strategy 
for the application of antimicrobial surfaces involves impregnating materials with soluble 
biocides that are released on contact there by rupturing and killing a biofilm forming 
microbe[203]. Another strategy involves the application of antimicrobial nanoscale 
surface morphologies. While nanomaterials derived from metal nanoparticles have been 
used extensively as coatings on medical devices, sanitation, wound dressings and also in 
food storage[204-207], antimicrobial nanostructured surfaces (NSS) are surfaces that 
inhibit microbial growth and viability using structural or mechanical cues.  NSS were 
originally identified on the wings of certain insects such as cicadas, but more recently 
these have been fabricated using techniques from the semiconductor industry and 
materials like polymers or metal oxides[208-210]. Recent work has demonstrated that the 
nanoscale architecture on the cicadas not only inhibits biofilm formation but also controls 
microbial development[211]. Research has demonstrated that surfaces with a high aspect 
ratio nanoscale architecture are lethal to many gram-negative bacteria like Pseudomonas 
aeruginosa, Escherichia coli, Pseudomonas fluorescens, and Branhamella 
catarrhalis[157, 212] as well as certain cellular yeasts such as Saccharomyces 
cerevisiae[213]. Cell physiology parameters like adhesion and cell wall rigidity play a 
role in cell-rupture, but there is a definite need to study underlying mechanisms involving 
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NSS-induced microbial rupture[214]. Biophysical models of bacterial cell interactions 
with nanopatterned cicada wing surfaces suggests that the bactericidal mechanism is 
biophysical and results due to a physical incompatibility between the cell and the surface 
without any specific biological interaction[153]. 
In this paper we determine and define the conditions and interactions of the fungi 
C. albicans with the nanostructured surfaces found on the wings of the dog day cicada, 
Tibicen tibicen.  In our studies we identify critical timing events associated with specific 
physiological and morphological features of the C albicans cell.  In our studies we 
demonstrate that the timing of C. albicans cell rupture depends on the timing of cell 
adhesion to the NSS and requires a cellular morphology rather than a hyphal form.   We 
also demonstrate for the first time that fungal cell differentiation is controlled by physical 
signals from the NSS  and may provide a novel means of controlling C. albicans 
virulence and pathogenicity at the interface between inorganic surfaces and human tissue, 
as in implants and other devices. 
2.2 Materials and Methods 
2.2.1 Yeast Strains and Cultures 
A wild type strain of Candida albicans (ATCC 90028) was grown in Sabouraud 
dextrose broth (SDB) at 250C in 50 ml conical flasks[215]. Depending on the 
experimental needs, cultures were grown to either mid-log phase at O.D~0.6 or to  
stationary phase at O.D.~2.0.  OD600 measurements were made using a Thermo Scientific 
Nanodrop 2000C spectrophotometer[216]. To induce hyphal growth, C. albicans hyphal 
forms are grown in a modified SDB media containing 10% bovine serum albumin (Sigma 
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F-3018) in 50ml conical flasks incubated overnight in a shaking incubator at 370C and 
200 rpm[217]. Hyphal growth can be identified by the formation of granular sediments in 
the growth media. 
2.2.2  Surface Preparation and Characterization 
We investigated the interaction of C. albicans cells with three different surface 
types: flat surfaces, a nano structured surface (i.e. a natural Cicada wing) and etched 
cicada wings which had submicron depressions.  We examined the interactions of the 
fungal cells on both native (i.e. uncoated surfaces) and Au-coated surfaces to control for 
differences in surface composition.  In the process, each of the type of surfaces (e.g. flat, 
nanostructured wings and etched wings), were coated with a 7nm layer gold using a 
Leica EM ACE200 and monitored in real time with a quartz crystal microbalance 
(QCM). For the experiments we used a flat glass coverslip as control. The cicada (Tibicen 
tibicen) wings used in the experiments were purchased from BioQuip Products, Inc., 
California. Wings from whole cicadas were carefully dissected from the organism so as 
to not damage their surfaces. Isolated wings were sonicated in 70% ethanol for 10 
minutes to remove any contaminants. Glass coverslips were cleaned using 70% ethanol 
and cleaned wings were then mounted on them using silicone glue (Silicone VC6-1/2).  I 
used flat glass coverslip as a control. As an additional control we used an etched modified 
cicada wing that we processed  using a PE-100-RIE Plasma Etch System etching the 
surfaces at 300FW power for 300 seconds. The plasma etched wing retained the general 
composition of the wing while removing all the nanocone architecture from the surface, 
revealing a surface dominated by submicron scale depressions. These etched wings serve 
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as negative control for all the experiments. The surface energy was measured via contact 
angle goniometry using a rame ́-hart 260-F4 contact angle goniometer and DROPIMAGE 
advanced software. A 3μl drop of deionized water was dropped on all the 3 different 
native and Au-coated surfaces and averages of 4 different repetitions on similar surfaces 
were calculated. 






Figure 2.1. Schematic representation of experimental methodology of C. 
albicans interaction with Cicada wing 
 
 
C. albicans cells were grown to desired O.D. and were labelled with calcofluor 
white (CFW) (Sigma-Aldrich, 18909) at 1:1000 concentration and Fun-1 cell stain 
obtained from (Molecular Probes F-7030) at 1:2000 concentration. The surfaces mounted 
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on the cover slip were placed in a PEGylated (Polyethylene glycol 8000) well of a 24 
well plate. A PEG treatment was used to inhibit the non-specific interactions of yeast 
cells with the walls of the 24well plate. The fluorescent labelled C. albicans cells were 
diluted with fresh SDB media at 1:3 ratio and 300µl of the diluted yeast culture is 
pipetted into each well. The viability as per FUN1 labeling and the chitin composition of 
the cell wall of cellular and hyphal yeast formed were monitored on the surfaces at these 
time points O hrs (T0), 2hrs (T2), 4 hrs  (T4), 8hrs (T8) 16hrs (T16), and 24hrs (T24) (Figure 
2.1). 
2.2.4 Quantifying the Densitometric Change from CLSM Data 
We monitored chitin levels in the C. albicans cell wall using the fluorescent dye 
Calcofluor white (CFW) and calculating the changes in its intensity in the confocal 
microscopy images using densitometry. I performed  a densitometric analysis using Zen 
Blue software on the fluorescent microscopy images captured by measuring the grey 
values of the intensity of the fluorescent dye detected. Densitometry values were 
collected from 100 cells images collected over ten different experiments for each surface 
and at each time point. 
2.2.5 Cell Viability 
To measure cell viability of C. albicans cells on the different surfaces, we used an 
MTT assay (Molecular probes V13154) and followed the protocol as described by the 
manufacturer. For these experiments, we grew C. albicans yeast cultures to an OD600 of 
0.6 which have  approximately 1x106 cells/ml and used 300μl of these cells that were 
cultured on the  different  surfaces for the MTT assay. Negative controls for these 
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experiments were replicates of C. albicans grown parallelly and treated with an 
antifungal drug (7 μg/ml) Voriconazole. 
2.2.6 Biofilm Quantification 
Biofilm formed on different nanostructured surfaces was quantified by a Crystal 
Violet  4Microtiter Dish Biofilm Formation Assay previously described[218]. The 
absorbance intensity of the crystal violet dye is measured using a BioTek Synergy Mx 
plate reader at 550 nm. 
2.2.7 Scanning Electron Microscopy (SEM) 
Candida albicans cells sampled were prepared on both the flat surfaces and the 
nanostructured cicada wings; cells were fixed overnight with 2.5% glutaraldehyde/2% 
formaldehyde solution in 0.1 M cacodylate buffer. The samples were them dehydration 
by an ethanol dehydration series of 30%, 50%, 70%, 95% and 100% for 10 min at each 
concentration. The samples are then dried and mounted on to aluminum SEM stubs and 
coated with a 5nm gold layer using Leica EM ACE200 equipped with real-time thickness 
monitoring using a QCM. The samples were then observed using a Zeiss Auriga scanning 
electron microscope. 
2.2.8 Microcolony Assay 
A microcolony assay was performed to test the effect of nanostructured surfaces 
on the morphogenesis of yeast to hyphae. A small volume 100μl of C. albicans yeast in a 
modified SBD media with the addition of 10% bovine serum albumin (Sigma F-3018)  
was inoculated on the various experimental and control surfaces and incubated at 370C 
overnight. C. albicans cellular forms that had been cultured in SBD media and C. 
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albicans hyphal forms that had been induced on glass coverslips served as negative and 
positive controls. To evaluate the microcolony assay, microcolony cultures on each 
surface were washed with PBS twice, labeled with CFW, and imaged using a confocal 
microscope as described. The results were  confirmed using SEM imaging as described 
above. 
2.3 Results 
2.3.1 Surface Characterization 
We examined the interactions of the yeast, C. albicans with three different surface 
 
nanoscale topologies: a flat topology (i.e. a 12mm round cover slip)(Fisherbrand 22- 
 
293232) a nanostructured topology that contained a ordered array of nanoscale cones that  
 
were 200nm tall, 200 nm wide with 30nm tips and spaced 200nm apart, (i.e. the wings  
 
from dog day cicada, (Tibicen ssp. [219].), and a nanoscale topology that consisted of an  
 
irregular arrangement of submicron depressions, (i.e. a  cicada wing that had been plasma  
 
etched) (Figure 2.2).  In addition to the ‘native’ uncoated surfaces we also examined  
 
surfaces that had been coated with a nanoscale layer of gold. Gold known for its  
 
biocompatible nature served as a control to maintain uniform surface chemistry in all of  
 
the test surfaces. Careful electron microscopy observations showed that gold nanoparticle  
 
coating on the cone surfaces retained the nanosurfaces aspect ratio coating the structures  
 
uniformly.  As part of our characterization, we examined the surface energy of these  
 
materials using contact angle goniometry.  We observed an increase in hydrophobicity  
 






decrease in the contact angle, which signifies a reduced  surface hydrophobicity on the  
 
Au-coated Cicada wing when compared to the native wing (table 2.1).  
 
 
Table 2.1. Contact angle of native and gold coated surfaces of different 
topologies 
Surface Contact angle 
Control-Glass cover slip 79.790± 0.090 
Au coated Glass 93.0750± 0.040 
Cicada 114.60± 0.070 
Au coated Cicada 87.0250± 0.130 
Etched Cicada 68.960± 0.060 





Figure 2.2. SEM images of experimental surfaces and visual representation of the 
topology of (1-A)(1-B) Flat surface, (2-A)(2-B)Nano-cone architecture on Cicada 
wing and (3-A)(3-B)Sub micron scale depressions on the Plasma Etched Cicada 
wing caused by the removal of nano-cones using Plasma etch process (4) Contact 




2.3.2 Adhesion of C. albicans on Different Nanostructured Surfaces 
Adhesion of microorganisms to substrates is the first step of pathogenesis.  
 
Microbial adhesion to inorganic materials depends on factors like surface roughness,   
 
hydrophilic/hydrophobicity of a surface, mechanical properties of the surface  and  
 
microbes innate sensory mechanisms that control cell-surface interactions[220].  To  
 
examine C. albicans adhesion with different surfaces we cultured both cellular and  
 
hyphal forms of C. albicans with the six different surfaces and examined the number of  
 















Figure 2.3. Adhesion of Candida albicans to different surfaces is observed to have 
increased with increase in incubation time (A) Flat glass surface (B) Nanostructured 
cicada wing and (C)Etched cicada wing at different time points (D) Summary of  
quantification of average number of cells per unit field of view with time. Each bar 
represents an average of cells per 10 fields of views done in five replicates. 
*denotes a P ≤ 0.05 and ** denotes a P ≤ 0.001 
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C. albicans polymorphs grown on different nanoscale topographies showed 
varying degrees of adhesion based on the age of the cells and time of incubation on the 
surface. On flat surfaces coated with 7nm gold we observed a gradual increase in the 
number of C. albicans cells/FOV as a function of the time of incubation. When compared 
among all the surfaces the number of cells/FOV were similar for the first eight hours, 
including the NSS surfaces of the cicada wing, plasma etched surfaces, surfaces coated 
with Au and native. However, at 16 hrs, we observed significantly fewer cells  on the 
nanostructured cicada wing surfaces when compared to the others. However, at 24hrs 
growth where most cells reach a stationary phase a decreased adhesion was identified on 
the Cicada wing and the etched Cicada wing when compared to the flat glass surface. 
This trend of reduced binding was  supported by the results of the MTT  assay which 
demonstrated a reduction of total cell metabolic activity from the yeast cells on the 
nanostructured cicada wing surfaces when compares to the control surfaces.  
2.3.3 Change in the Cell Wall Composition of C. albicans on Different NSS 
Chitin is a major component of the yeast cell wall and is critical for the 
mechanical stability of the yeast cell[221]; mechanical challenges to a yeast cell wall has 
been shown to alter the cell wall chitin biosynthesis[222]. To determine whether contact 
with a nanostructured surface alters the chitin content of the C. albicans cell, we 
quantified cell wall chitin by labeling chitin using the fluorescent dye CFW and 
monitoring the change in its intensity using live-cell confocal microscopy. We observed 
an increase in CFW fluorescence in cells that were in contact with the nanostructured 
cicada wing when compared to the glass and etched wing surfaces (Fig 2.4). The intensity 
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of CFW increased with the time of exposure to the nanostructured cicada wing 
suggesting that the C. albicans cells in contact with the wing were responding to a 
mechanical stress caused by nano-cone arrays.  In contrast, from (figure 2.4.) we 
observed a reduction in CFW fluorescence from C. albicans cells cultured on the Au-
coated etched wing surfaces when compared to the Au-coated flat glass surface). The 
Chitin level in the cell wall of C. albicans on initial contact were significantly higher and 












Figure 2.4. Changes in cell wall composition represented by change in chitin in cell 
wall labelled by CFW fluorescent dye. (a)Native Cicada wing (b)Au-coated Cicada 
wing. The chitin levels in the C. albicans yeast on all the surface decrease with 
increase in incubation time.  
*denotes a P ≤ 0.05  
 
 
2.3.4 C. albicans Viability and Rupture of Nanostructured Surfaces 
To correlate yeast cell adhesion with the viability of the C. albicans cells on our 
surfaces, we labeled log phase (O.D.~0.6) yeast cells using the vital dye FUN1 and 
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observed these cells using confocal laser microscopy. FUN1 is a ratio metric cell-
permanent vital dye that is processed by living, metabolically active fungal cells; the dye 
upon cellular uptake fluoresces red upon excitation with a blue light, however, in 
metabolically active cells the dye is enzymatically processed to a product with green 
fluorescence[223]. We observed a time-dependent reduction in viability in C. albicans 
cells that have been in contact with the nanostructured cicada wing surfaces both native 
and Au-coated (Fig 2.5) as indicated by the reduction and/or loss of the red FUN1 
fluorescence in these cells. We did not observe significant loss of the green FUN1 
fluorescence in cells incubated on flat or etched surfaces (Fig 2.5). The maximal amount 
of timing of the loss of green FUN1 fluorescence coincided with the reduced adhesion of 
C. albicans cells to the nanostructured wing surfaces, i.e. at 8 hrs. I observed loss of 
viability of C. albicans cells on the etched wings, but it was not consistent and significant 
at all the incubation time points (Figure 2.5). To confirm that the loss of metabolic 
activity as determined by FUN1 staining was in fact due to loss of viability we examined 
the state of the cells on all surfaces using SEM.  Previous work demonstrated that the 
nanostructured surfaces of the dog day cicada rupture yeast cells from a different 






Figure 2.5. Cell viability of W.T. Candida albicans stained with fluorescent dye 
FUN-1. the green cells indicate the live cells and the red cells represent the 
dead/ruptured cells on different surfaces (A) Flat glass surface (B) Nanostructured 
cicada wing and (C)Etched cicada wing at different time points (D) Quantification 
of percentage of cell rupture on different Nano topological surfaces. Each bar 
represents the average percentage of cell ruptured per 10 fields of views done in five 
replicates. 




Figure 2.6. LDH and MTT cell toxicity and cell metabolic activity assay on C. 
albicans on NSS: LDH cytotoxicity assay showing increase in rupture of C. albicans 
up to 16 hours of incubation on nanostructured Cicada wing normalized by Control 
glass and positive control C. albicans treated with antifungal drug. (1-B) MTT assay 
representing a higher cell metabolic activity of C. albicans on control glass surface 
when compare to nanostructured surfaces indicating these NSS decrease adhesion 
and cell proliferation 
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C. albicans cells on the nanostructured surfaces found on the dog day cicada wing 
also rupture, thus demonstrating that the loss of metabolic activity observed by FUN1 
was due at least in part to disruption of cell integrity. Rupture of C. albicans cells on the 
nanostructured surfaces of the cicada wing was further supported by an LDH cell toxicity 
assay, which measures the results of an intracellular enzyme upon the compromise of 
cellular integrity[225]. The results from LDH assay have a similar trend with the FUN1 
results and show an increased release of LDH from C. albicans cells with an increase in 
incubation time on the nano-structured cicada wing surfaces up to 16 hours. However, 
from figure (2.6) we observe a decrease in LDH release from C. albicans cells at 24-hour 
incubation which correlate with enhanced biofilm production at this time. 
2.3.5 Surface Structure and Biofilm Formation 
Many microbes including cellular yeast respond to contact with different 
materials by altering their formation of a mature biofilm[60]. To determine whether C. 
albicans produces different production using a Crystal violet assay[226]. From figure 
(2.7) I observed, crystal violet intensity which is a measure of biofilm formed to be 





Figure 2.7. Change in biofilm formation of Candida albicans quantified by crystal 
violet assay on different structured surfaces.  
*denotes a P ≤ 0.05 and ** denotes a P ≤ 0.001 
 
 
2.3.6  Interactions of Hyphal C. albicans  with Nanostructured Surfaces 
C. albicans is a polymorphic fungus that exists in several distinct morphological 
forms including a hyphal form that is associated with virulence[227]. To determine 
whether the hyphal form of C. albicans behaved differently on the nanostructured 
surfaces, we differentiated C. albicans cells to form hyphae, incubated on our 
experimental surfaces and observed their behavior. From the scanning electron 
microscopy images in figure (2.8), I observed no differences in adhesion, viability or cell 
integrity of hyphal C. albicans on any surface suggesting that this morphological forms 





Figure 2.8. Scanning electron micrographs of interaction of Candida albicans 
WT on (A-C) control flat glass surface where the cell structure remained intact even 
at longer interaction times and increase in colonization of yeast is observed with 
increase in incubation time (D) Healthy C. albicans yeast on Nanostructured Cicada 
wing at 0-hour incubation (E) ruptured C. albicans yeast cell on the cicada wing 
after 8-hour incubation (f) areas with the remnants of cells and cell debris of 
ruptured/dead C. albicans yeast on Nanostructured Cicada wing after 24-hour 
incubation (G-I) represents the C. albicans yeast  on plasma Etched Cicada wing 
where cells show no damage and also an increased adhesion and colonization with 
increase in incubation time. 
 
Table 2.2. Effect of surface topography on the morphogenesis of Candida albicans on 
different surfaces. 
 
 Control Glass Cicada wing Etched Cicada 
Morphogenesis of 
C. albicans WT 





Figure 2.9. Micro colony assay demonstrating the effect of NSS on the 
Morphogenesis of C. albicans from Yeast to Hyphae. From (A) glass surface and (B) 
etched Cicada surface showed no effect on morphogenesis of C. albicans. (C) Cicada 
wing surface inhibits the differentiation of yeast to hyphae. 
 
 
Although no changes to viability or adhesion of the hyphal forms of C. albicans 
were observed, I did observe an alteration in the ability of C. albicans to change its 
morphology when in contact with the nanostructured surface of the dog day cicada (Table 
2.2, Fig 2.9). The morphogenesis of cellular form to the hyphal form is an important 
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event of pathogenesis in the life cycle of C. albicans[228].  Many different 
environmental conditions result in the switch from a cellular of C. albicans to a hyphal 
morphology including nutrient levels, temperature, and cell numbers[229].  
Experimentally the addition of serum to the culture medium results in a switch to a 
hyphal form[27].  C. albicans microcolonies cultured on flat glass substrates in a 
modified SDB medium that contained 10% bovine albumin serum  exhibited tubular 
hyphal morphology as demonstrated by  confocal laser and SEM micrographs (Fig 2.9 
A). Etched wing surfaces with C. albicans microcolonies cultured under similar growth 
conditions also exhibited a similar  transformation from yeast to hyphae although not 
nearly as pronounced as those on flat substrate and primarily presented as pseudo hyphal 
formation (Fig 2.9 B) . However, the microcolonies of C. albicans cultured on the 
nanostructured arrays found on the wings of the dog day cicada had no hyphal formation 
(Fig 2.9 C). 
2.4 Discussion 
The range of microbial cells that rupture on these surfaces supports this 
conjecture. However, there are two caveats to this model. First, different microbes engage 
surfaces differently and a purely biophysical model for rupture demands the identification 
of a common mode of surface engagement by all microbes.  Second, if NSS interactions 
are mechanical then a pure physically incompatible model would need to account for the 
differences in the mechanical and/or morphological properties of microbes.  These two 
caveats suggest that the mechanism for microbial cell rupture by NSS may be more 
complex. The mechanism of rupture of pathogenic fungal cells is crucial when designing 
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antifungal surfaces[230, 231]. The need for novel biocompatible antimicrobial surfaces is 
gaining importance especially with increasing  infections of multidrug resistant strains 
and failure in indwelling medical devices[232, 233]. While antimicrobial surfaces are not 
new, rupture inducing NSS operates in a manner that is contrary to the strategies of 
previously conceived anti-microbial surfaces; that is, NSS promote and require stable 
cell/substrate adhesion rather than inhibit it[234]. Research on interactions of anti-
microbial nanostructured surfaces and bacteria is being widely studied but the interaction 
of much important pathogenic fungi on the nanostructured surfaces needs to be 
explored[235, 236]. Although there is a great potential for NSS application, there are no 
clearly defined limitations of NSS as a mechanical control of fungal growth, or how a cell 
may develop resistance; by studying the mechanism of NSS rupture, this study will also 
be the first to study this aspect of NSS in any system. 
 With an increasing number of drug resistant strains of microbes and 
emerging superbugs the need for alternate techniques to tackle these deadly microbes is 
becoming eminent. Fungal super bugs like Candida auris of the same family as Candida 
albicans are resistant to most available fungal drugs available in the market either 
directly or also in combinations[237]. Unlike its other family species C. auris has the 
ability to proliferate outside the host body and proliferates rapidly in the environment 
specially on Hospital beds/apparel, heart rate monitors, I-V piping, and sanitation areas, 
increasing the chances of reinfections[238]. Though spraying antifungal agents and use of 
harsh chemicals temporarily solves this problem but in a longer time frame in turn leads 
to the evolution of antifungal species of microbes and other superbugs[52]. 
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Anti-microbial coating on surfaces is an ideal addition to existing anti-microbial 
techniques as they can be used as coatings on all the surface prone to multi-species 
microbial fouling and also on indwelling medical devices which significantly raise the 
lifespan of these implants. Though anti-microbial efficiency of naturally evolved 
nanostructured anti-microbial surfaces were previously studied on both gram positive and 
gram-negative bacteria their interaction with a much complex fungal system was only 
briefly studied. In this study we demonstrate the antimicrobial efficacy of nanostructured 
surfaces against a harmful pathogenic fungus Candida albicans. The adhesion and 
biofilm formation of Candida albicans yeast varied significantly when interacted with 
different nanostructured surfaces. The inhibition of microbial adhesion displayed by the 
Cicada wing compared to the control glass surface or etched cicada wing confirmed the 
role of nano-cones on the surface interaction with microbes. Biofilm formation which is 
responsible for failure of many indwelling medical devices and a root cause for most 
Candida related infections was also significantly reduced when incubated on the NSS 
than flat surfaces. This demonstrates the role and need to integrate these NSS as surface 
coatings on various medical devices and catheters to enhance their life span and reduce 
further secondary infections. The rupture/death of various bacteria and S. cerevisiae on 
native NSS were previously demonstrated but the in-depth interaction with pathogenic 
fungi or timing of rupture by these NSS was ignored.  The NSS exhibited contact killing 
abilities by rupturing C. albicans yeast on prolonged interaction with the NSS. The 
interaction time required to rupture the pathogenic yeast was a lot higher than bacterial 
cells which is attributed to the higher complexity of the fungal cell wall when compared 
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to bacteria. NSS-C. albicans interactions exhibited a change in chitin concentration in the 
fungal cell wall  which is predicted to be a mechanical stress response of the yeast due to 
the NSS assault. 
We observed the role played by the formation of biofilm in the inhibition of 
rupture and increased adhesion on the substrates. From the (fig 2.6) LDH cell assay 
performed on the control and the Cicada wing showed an increase in cytotoxicity till 16 
hours incubation in the nutrient rich conditions, a sudden decrease in cytotoxicity at 24 
hours was observed which is attributed to the excess biofilm formation which block the 
fungicidal interactions between the cones and C. albicans. Though the hyphal structures 
of C. albicans did not exhibit any morphological damage on interaction with the nano 
structured surfaces we observed an effect on the morphogenesis from yeast to hyphae on 
these surfaces. The hyphal transformation inhibition on the Cicada wing was observed on 
both control glass and etched cicada surface confirming that the nano cones have a 
definite effect on the morphogenesis cycle. We predict the mechanical stress induced by 
the nano cones on the yeast might impact the cell wall biosynthesis pathways which are 
essential for the morphogenesis and a detailed genomic analysis is required to confirm it. 
The nano structured cicada wing exhibited excellent antimicrobial characteristics like 
inhibiting the adhesion of C. albicans, rupturing the cellular yeast on prolonged contact 
and also controlling the pathogenicity by inhibiting the morphogenesis pathway proving 





INTERACTION OF DRUG RESISTANCE STRAINS OF CANDIDA ALBICANS 
 




The past decade has witnessed a significant increase in the development of 
resistance to antibacterial and antifungal agents primarily due to the misuse of antibiotics 
and evolutionary changes in microbes[239]. Globally, deaths attributed to antibiotic 
resistance in bacterial infections is more than 700,000 every year and is expected to reach 
10 million by 2050[240]. Failure to eradicate a fungal infection from a patient by the use 
of an antifungal drug which was previously used or demonstrated proven antimicrobial 
efficacy is called Clinical resistance. Mycological resistance is the in-vitro resistance 
developed by fungi to the agents which were previously susceptible. Antifungal 
resistance is a growing concern in the field of medical mycology, predominantly in 
human commensals like Candida albicans which turn pathogenic during sickness or in 
immune deprived patients like patients suffering from HIV. This is a leading cause of 
health care associated infections[241]. 7-15% of all Candida bloodstream isolates tested 
were resistant to fluconazole and the drug resistance is higher in other Candida species 
like C. glabrata and C. parapsilosis. 20–30% of candidemia cases involve species with 
intrinsic resistance to either fluconazole or echinocandins[242]. In the past few years, 
significant attention is given to understand the mechanisms of antimicrobial resistance, to 
improve detection and find alternative methods to tackle antimicrobial resistance[243]. 
53 
 
Most of the antimicrobial research is focused on bacterial resistance primarily as they 
account to a large fraction of human infections. Until recently, fungal species are not 
identified as serious pathogens but their ability to turn pathogenic causing infections on 
indwelling medical implants and co-existing with other deadly bacterial species, made the 
study of molecular mechanisms of resistance and innovation of alternate antifungal 
techniques against resistant species necessary[244]. Interactions between sterols and 
phospholipids in the plasma membrane of yeast affect the membrane fluidity and 
asymmetry and consequently influence the transport of materials across the 
membranes[243]. A decrease in the amount of drug taken up by the fungal cell may result 
from changes in the sterol and/or the phospholipid composition of the fungal cell 
membrane. 
Mechanisms by which fungal cells may develop resistance[245] 
1) The target enzyme is overproduced, so the drug becomes inefficient to inhibit 
the biochemical reactions 
2) The target drug is altered so the drug cannot bind to the target 
3) The drug administered is pumped out by an efflux pump. 
4) Fungi develop mechanisms to inhibit the entry of drug at the cell 
membrane/cell wall 
5) Cell develops mechanisms to compensate the loss of function caused by the 
drug 
6) Nonessential enzymes targeted by the fungal drugs are inhibited 








Therapy for Candida infections has been difficult because of the limited number  
 
of available antifungal agents. Though Amphotericin B is administered against many  
 
infections caused by different Candida sps., it is associated with many nonspecific  
 
toxicities and requires intravenous administration[246]. Until recently, Azole drugs were  
 
the first choice as they are bioavailable after oral administration but the increase in MIC  
 
rates due to developing resistance made it impossible[247, 248]. Azoles treat fungal  
 
infections by interfering with the enzyme lanosterol 14-a-sterol demethylase involved in  
 
ergosterol biosynthesis, a prominent component of the fungal cell wall, and is a  
 
promising antifungal target. This interference causes inhibition of fungal growth by  
 
altering the structure and function of the cell membrane[249]. Azole selectively targets  
 
fungal cells as their major target components chitin, glucan and mannose are all absent in  
 
human cells and the fungal cells also exhibit differently structured ergosterol and  
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cholesterol compared to the host[250]. Commonly used azole derivatives such as  
 
fluconazole, itraconazole, and voriconazole partly target the inhibition of cytochrome P- 
 
450-dependent 14α-sterol demethylase[245]. There are no evidences demonstrating  
 
modification of azole antimicrobials as a mechanism of resistance. Resistant strains  
 
exhibit a modification in the quality or quantity of target enzyme, reduced access to the  
 
target, or some combination of these mechanisms. Overexpression of 14α-demethylase  
 
which results in the increase in ergosterol synthesis has been implicated as a mechanism  
 
of resistance to azole antifungals. Candida albicans can become resistant to azoles by  
 
increasing the number of efflux pumps in the cell which are simple membrane associated  
 
transporters and prevent intracellular accumulation of the drug[107, 251, 252]. Table 3.1. 
 
summarizes the biochemical mechanisms of azole resistance in C. albicans.  
 
 
Table 3.1. Biochemical basis of azole resistance[243] 
 
Mechanism Caused by: Result 




Mutations which alter drug 
binding but not binding of the 
endogenous substrate 
  
Target is active (i.e., 
can catalyze 
demethylation) but has 
a reduced affinity 
towards azoles 
Alteration in sterol 
biosynthesis 
  






instead of ergosterol 
Reduction in the 
intercellular 
concentration of target 
enzyme 
Change in membrane lipid and 
sterols; overexpression of 
specific drug efflux pumps 
(CDR1, PDR5, and BENr) 
Poor penetration 
across the fungal 




Mechanism Caused by: Result 
Overexpression of 




Increased copy number of the 
target enzyme 







With the increasing resistance of azole class of antifungal drugs in Candida sps.,  
 
the use of Echinocandins have proven to be effective. Lipopeptidic echinocandins  
 
interfere with glucan synthesis of the cell wall[253] by inhibiting the synthesis of -1-3 D  
 
glucan synthase. Most anti-fungal drugs target -1-3 D-glucan, a critical cell wall  
 
polysaccharide as it is present in all yeast cells and acts by selectively targeting the yeasts  
 
cells in the host system[254]. Echinocandins cause impaired fungal cell wall formation  
 
that can result in osmotic lysis, makes the fungal cell vulnerable to external stresses  
 
causing fungal cell death[255]. In addition to being efficacious for the treatment of  
  
invasive candidiasis, the echinocandins are also advantageous due to their lack of  
 
clinically significant drug-drug interactions and adverse effects[256, 257]. The prolonged  
 
use of Echinocandins has led to development of resistance in Candida albicans causing  
 
recurrent Candidemia specially in immunocompromised patients. First reported cases  
 
were from HIV infected patients suffering with esophageal candidiasis due to continuing  
 
immunosuppression secondary to their viral infection[258, 259]. In the recent times,  
 
Echinocandin resistance in Candida sps. is increasingly seen in infections caused in  
 
implant recipients and is mostly attributed to the mutations caused in FKS1 and FKS2  
 







common in fungal species. Candida albicans has shown a 1000-fold greater drug  
 




Figure 3.2. Primary targets and mode of action by azoles and echinocandins[251] 
 
 
With emergence of multidrug resistance in Candida sps. affecting hospital 
 
settings and patients globally[261], the need for alternate approaches to tackle the  
 
antimicrobial resistance is gaining prominence. Antimicrobial surfaces have proven to be  
 
effective, even on the drug resistant strains of microbes and there is no known  
 
mechanism which can develop resistance to the mechanical stress induced by  
 
antimicrobial surfaces. Coating surfaces in healthcare environment with antimicrobial  
 




recontamination in a sustained manner[262]. Approaches such as combined therapies to  
 
stop emergence of resistant species, where two or more biocides are used simultaneously,  
 
have shown to inhibit pathogenic microorganisms as well as their proliferation by  
 
promoting further mechanisms for microbe killing[263]. 
 
 
Table 3.2. Candida albicans drug resistant strains of ATCC MP-8 panel used in this 
study 
 
Candida albicans strains Resistant Drugs Isolation Source 
Candida albicans 
WT (ATCC 90028) 
None Blood, Iowa 




Candida albicans (ATCC 11651) Itraconazole 
Lung pus, 
Virginia 




fluid of a 6-
month-old infant, 
Dallas 








Candida albicans (ATCC 90029) 5-flucytosine Blood, Iowa 
 
 
In the previous experiments, we have demonstrated the efficacy of native 
nanostructured surfaces as anti-fouling & biocidal and also inhibiting virulence in 
pathogenic fungi C. albicans. We aim to determine the behavior of drug resistant strains 
of C. albicans of ATCC MP-8 panel, listed in table (3.2), which have shown resistance to 
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one or more antifungal drugs such as anidulafungin, micafungin, caspofungin, 
5-flucytosine, voriconazole, itraconazole, and fluconazole.  
3.2 Material and Methods 
Candida albicans strains listed in table (3.2) purchased from ATCC were stored  
 
in -800 C freezer. For each experiment, colonies from freshly streaked plates were grown  
 
in Sabouraud dextrose broth (SDB) (peptone, dextrose, water) at 250C in 50 ml conical  
 
flasks with shaking ≈ 150 rpm to an early-log phase measured at OD~0.5 where cells are  
 
metabolically active. All the work with drug resistant strains was conducted following  
 
BSL-2 laboratory guidelines. The cells were later labeled with florescent dyes Calcofluor  
 
white and FUN-1 for enumeration on different surface topologies and to determine their  
 
viability as previously described in (2.2.3). Anti-fungal susceptibility tests were  
 
performed using Fluconazole (Sigma-Aldrich PHR1160) Itraconazole (Sigma-Aldrich  
 
PHR 1834) Voriconazole (Sigma-Aldrich PHR 1892) 5-flucytosone (Sigma-Aldrich  
 
F0175000) and Anidulafungin (Sigma-Aldrich SML2288) by making drug stocks in  
 
DMSO(Sigma-Aldrich 276855) and water, where the final concentration of DMSO was  
 
less than 1%. Susceptibility of these resistant strains of C. albicans to their respective  
 
drugs was done by serial dilution method where the OD600 values were measured using  
 
BioTek Synergy Mx plate reader. Stock solution for all the drugs were prepared  
 
following the CLSI susceptibility range for Candida albicans[264]. Tables (3.3) and  
 
(3.4) are the standard dilution factors for specific solvents to be used for the drugs for  
 
clinical and laboratory use. Biofilm formation of all the drug resistant strains of C.  
 




chapter 2. All the control glass surfaces, and nano structured cicada wings used in this  
 
study were coated with a 7nm layer of gold using a Leica EM ACE200 with a real time  
 
thickness monitoring quartz crystal microbalance (QCM). 
 
 
Table 3.3. Scheme for preparing dilutions of water-soluble antifungal drugs to be 





Table 3.4. Scheme for preparing dilutions of water-insoluble antifungal drugs to be 






Quantification of Biofilm formed by Candida albicans of various strains on 
nanostructured surfaces was measured using crystal violet technique of biofilm 
quantification as previously described. Statistical analysis was done using single factor 
Anova on Microsoft Excel. Scanning electron microscopy was performed on all samples 
to confirm the results. Same protocols for confocal and scanning electron microscopy 
described earlier were followed for imaging the drug resistant strains. 
3.3 Results 
3.3.1 Minimum Inhibitory Concentration of Anti-fungal Drugs to C. albicans 
Mutant Strains 
The antifungal action on the Candida sps. by the drugs was observed to be dose 
dependent and was found to vary with the change in number of cells. Susceptibility of C. 
albicans strains to antifungal drugs obtained by serial dilution method was in coherence 
with the data available from Clinical & Laboratory Standards Institute (CLSI). 
Fluconazole drug resistant strain C. albicans 96901 showed an increase in MIC compared 
to other antifungal drugs and the wild type. C. albicans strains specifically resistant to 
other azole drugs like voriconazole and itraconazole showed an increase in MIC required 
for C. albicans strains ATCC 11651 and ATCC 90029. The MIC required was quantified 
for all the Candida strains at a concentration of 30,000 cells/ml to all the used antifungal 
drugs was in table (3.5). Candida mutants exhibiting to specific resistant drug have 







Table 3.5. In-Vitro activity of antifungal drugs fluconazole, itraconazole, 
voriconazole, anidulafungin and 5-flucytosine against various drug resistant 




3.3.2 Adhesion and Viability of Drug Resistant Strains of C. albicans on NSS 
of Cicada Wing 
Drug resistance developed in C. albicans depends on various crucial mechanisms, 
most of them related to the cell wall bio synthesis pathways. In these experiments, I aim 
to determine how different strains of Candida albicans with specific resistance developed 
to anti-fungal mechanisms respond to the mechanical stress induced by the nano cone 
structures of the Cicada wing.  
3.3.2.1 Interaction of Fluconazole Resistant C. albicans 96901 with NSS 
Candida albicans yeast resistant to fluconazole, the most commonly used 
antifungal drug of the class azoles, is interacted with nano structured surface of the 
Cicada wing and a glass cover slip as control to study adhesion and cell viability of the 
drug resistance mutants. From the confocal microscopy images (figure 3.3), I observe an 
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increase in the number of cells on the surface with an increase in the incubation time, 
primarily as the cells replicate and increase in number with time. Quantifying the number 
of cells, figure (3.3) shows no significant change in the initial adhesion of the C. albicans 
cells on the nano structured surface of the Cicada wing at incubation time 0 hours and 8 
hours compared to the NSS. But the adhesion of Fluconazole resistant C. albicans at 
incubation time of 16 hours is significantly (P ≤ 0.05) lower on NSS compared to the 
control glass.  
The cell viability data from the Fun-1 fluorescent assay showed an increased 
percentage rupture of fluconazole resistant yeast on the NSS when compared to the flat 
surfaces. At 16 hours of incubation, we observed a significant (P ≤ 0.001) mortality of 
cells on the NSS compared to the control surface. Though the rupture of these resistant 
cells is comparatively less than the wild type, it is higher than the control surfaces, 






Figure 3.3. Confocal microscopy studies of fluconazole resistant C. albicans 
96901 on NSS of Cicada wing. Each bar graph represents average of data collected 
from 10 field of views. 









3.3.2.2 Interaction of Itraconazole Resistant C. albicans ATCC 11651 with 
NSS 
Itraconazole is also a member of the azole class of antifungal drugs and acts by 
 
acting on the 14α-sterol demethylase involved in ergosterol biosynthesis yielding changes  
 
to the plasma membrane. The adhesion behavior of these C. albicans 11651 which have  
 
developed resistance by acting on the cell wall biosynthesis pathway like C. albicans  
 
96901 was very different. From the figure (3.4) itraconazole resistant fungi showed very  
 
little adherence to both flat and structured surfaces but for the adhered cells, though not  
 















Figure 3.4. Confocal microscopy studies of Itraconazole resistant C. albicans 
11651 on NSS of Cicada wing. Each bar graph represents average of data collected 
from 10 field of views. 









3.3.2.3 Interaction of Caspofungin and Anidulafungin Resistant C. albicans 
ATCC 76485 with NSS 
Candida albicans mutants have developed resistance to echinocandin class of 
antifungal drugs which acts by reducing the cell wall rigidity. When these yeast cells 
were inoculated on the NSS of the Cicada wing and flat glass surface figure (3.5), a 
reduced adhesion of these cells to all the surfaces was observed. Echinocandin resistant 
cells at 16 hours of incubation showed a significant decrease in number of cells adhering 










Figure 3.5. Confocal microscopy studies of anidulafungin and caspofungin 
drug resistant C. albicans on NSS of Cicada wing. Each bar graph represents 
average of data collected from 10 field of views. 
*denotes a P ≤ 0.05; ** denotes a P ≤ 0.001 
 
 
With fewer cells adhering to the surface, the cell viability on the control and test 
surface did not show any significant change in cell viability with increase in incubation 
time of yeast on the surfaces. I predict that the echinocandin resistant mutant cells of C. 
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albicans have a thicker cell wall compared to the wild type strains as a physiological 
adaptation by which antifungal resistance is developed, which is responsible for the 
anomalous behavior on these surfaces. 
3.3.2.4 Interaction of Multidrug Resistant C. albicans ATCC 10231 with NSS 
Candida albicans yeast 10231 are mutants that have developed resistant to 
multiple azole and echinocandin class of drugs like fluconazole itraconazole, 
voriconazole anidulafungin and caspofungin were inoculated on flat and NSS to study 
their cell viability and adhesion behavior. From the confocal microscopy images, an 
overall low adhesion tendency of mutants compared to wild type strains was observed. 
The adhesion of these mutant cells was found to be significantly (P ≤ 0.001) low at 0-
hour and 8-hour incubation on NSS of Cicada wing when compared to the flat glass 
surfaces. A slight increase in the percentage of cell death was observed on the NSS at all 
time points compared to the controls but the cell rupture efficiency towards these mutants 






Figure 3.6. Confocal microscopy studies of azole and echinocandin class drug 
resistant C. albicans 10231 on NSS of Cicada wing. Each bar graph represents 
average of data collected from 10 field of views. 









3.3.2.5 Interaction of Flucytosine Resistant C. albicans ATCC 90029 with 
NSS 
Of all the C. albicans drug resistant mutants we worked on, flucytosine resistance 
strains differ in the mechanism of development of resistance. Flucytosine drug is an 
effective antifungal by affecting the nucleic acid of the fungi and these mutants develop 
resistance by blocking the nucleic acid damage. Flucytosine resistant C. albicans strains 
showed an increase in the number of cells adhering with an increase in incubation time 
on the substrates but the adhesion of C. albicans cells on the flat glass surface versus 
NSS of cicada wing showed no significant change. However, the cell viability assay of 
these strains of fungi on the substrates confirmed an anti-microbial response of the NSS  
with a significant number of cells showing cell damage compared to those on the control 






Figure 3.7. Confocal microscopy studies of 5-flucytosine drug resistant C. albicans 
90029 on NSS of Cicada wing. Each bar graph represents average of data collected 
from 10 field of views. 









3.3.3 Biofilm Formation of Drug Resistant Strains of C. albicans on 
Nanostructured Surface of the Cicada Wing 
Biofilm formation is a crucial step in the evolution of resistance to specific 
 
antifungal drugs and for the virulence in Candida albicans. The first step for biofilm  
 
formation is the adhesion of microbes to the surface. Change in adhesion of different  
 
drug resistant strains of C. albicans ultimately affects the biofilm formed on the surface.  
 
The biofilms formed by all the mutant yeast strains of C. albicans grown on the control  
 
glass surface and NSS of Cicada are stained with crystal violet dye and absorbance at  
 
550nm is measured. From the figure (3.8) I observe an inhibition in the biofilm formation  
 




Figure 3.8. Biofilm formation of various drug resistant and wild type strains of C. 
albicans on flat glass surface and NSS of Cicada wing. 








3.3.4 Effect of NSS on the Morphogenesis of Drug Resistant Strains C. 
albicans 
Candida albicans turns pathogenic by transforming from cellular yeast to tubular  
 
hyphal form. This morphogenesis is modulated by many factors including a thigmotropic  
 
response where the hyphal orientation and formation is dependent on the adhesion of  
 
yeast to the substrate. The micro colony assay performed on these specific drug resistant  
 
strains of C. albicans showed altered responses in the morphogenesis on the NSS and flat  
 
surface (Table 3.6). The morphogenesis in resistant strain 96901 showed an inhibition of  
 
morphogenesis when inoculated on Cicada wing but showed hyphal structure formation  
 
on flat glass cover slip. A similar response was observed in C. albicans 11651 which has  
 
developed resistance to an azole class drug itraconazole. The morphogenesis experiments  
 
in anidulafungin and caspofungin resistant 76485 showed no effect of NSS on the  
 
morphogenesis and formed hyphae. The multi drug resistant strain also showed similar  
 
response on the NSS and control and formed hyphae. C. albicans 90029 had an influence  
 
of the nano structured surface in the inhibition of hyphal formation but transformed into  
 
hyphae on the flat surface. 
 
 
Table 3.6. Effect of NSS on the morphogenesis of yeast to hyphae in drug resistant 
strains of C. albicans. indicates the formation of hyphae and  indicates the 







Figure 3.9. Confocal micrographs showing the effect of NSS on the morphogenesis 




Drug resistance in microbes is a growing concern specially in commensal fungi 
like Candida albicans which turn pathogenic and is a serious concern in implant 
recipients and immunocompromised patients. In this proposed study of alternative 
antifungal approach using nanostructured surfaces to tackle drug resistance, I focused on 
three important phases of Candida life cycle i.e. adhesion, maturation (biofilm formation) 
and virulence. The azole class  of antifungal drug acts by inhibiting the 14α-demethylase 
involved in ergosterol, an important component of fungal cell. The anti-fungal resistance 
developed in C. albicans mutants retain the ergosterol biosynthesis and maintain 
homogeneity in the fungal cell wall. When Fluconazole, an azole class drug resistant 
strain was exposed to NSS assault, I found similarity in cell rupture and adhesion 
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behavior of these strains and the wildtype. However, when mutants exhibiting resistance 
to another azole drug itraconazole was interacted with NSS, a dramatic inhibition in 
adhesion to all the substrates compared to fluconazole resistant or the wild type strains 
was observed, indicating the complexity in behavior of Candida albicans. Echinocandins 
on the other hand owe their antimicrobial activity by decreasing the cell wall rigidity and 
damaging cell integrity. I predict the mutants which exhibit a developed resistance in 
echinocandins compensate the loss of cell wall thickness and have a thicker cell wall. 
NSS interaction of the fungin drug C. albicans exhibited decreased adhesion on all the 
substrates like the itraconazole resistant and no effect on the cell viability by the NSS 
induced stress, demonstrating failure of these nanostructured surfaces to induce anti-
microbial effect to these thicker cell-walled pathogens. The behavior of multidrug 
resistant strain of C. albicans was in coherence with the echinocandin resistant strain. 
Flucytosine resistance is developed by blocking the nucleic acid damage caused by the 
drug and there was no proven mechanism demonstrated that brings in changes to the cell 
wall composition or structure in the evolution of fluconazole resistance. Rightfully so, the 
flucytosine resistant strain exhibited similar response in cell adhesion and viability to the 
wild type strains of C. albicans.  
Biofilm formation is the key step in Candida albicans, protecting the cells from 
external shocks, action of drug efflux pumps, adhesion to surface and proliferation of the 
microbial community. The biofilms caused by drug resistance are an important health 
concern as they are always mis diagnosed which can lead to systemic infections in host. 
The drug resistance in biofilms formed by C. albicans on the implants and indwelling 
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medical devices highlighted the need to control and tackle biofilms formed to reduce 
infections. Nature of substrate plays a key role in the microbial adhesion and research 
pertaining to the changes in adhesion and biofilm formation by different microbes on 
various surfaces was well studied. The inhibition of biofilm formed by drug resistance 
strains of C. albicans on the Cicada wing compared to the flat surface is accounted to 
various responses of the yeast to surfaces like decreases adhesion to structured surfaces 
compared to flat surface, rupture of cells leading to a decrease in number of cells capable 
of secreting biofilm matrix.  
Nanostructured surface of Cicada wing also proved to have an effect on the 
morphogenesis on the drug resistant mutant strains of Candida albicans. The thickness 
and composition of cell wall play a very important role as the echinocandin resistant 
strains of C. albicans predicted to have a thicker cell wall as a drug resistant response, 
this did not show any inhibition of morphogenesis on NSS of Cicada wing like the wild 
type strain. Multidrug resistant mutant of C. albicans showed no effect of NSS in the 
yeast to hyphae transformation. There are no confirmed mechanisms in flucytosine 
antibiotic activity that involve any changes in cell wall biosynthesis pathways and C. 
albicans resistant to flucytosine showed an inhibition in hyphal formation when 
incubated on the NSS of Cicada wing. C. albicans mutants resistant to most  azole class 
of antifungal drugs when inoculated on the NSS showed  inhibition in the morphogenesis 





NANO STRUCTURE MODIFICATIONS OF SILICONE CATHETER TO 
 
IMPROVE THE ANTIMICROBIAL ACTIVITY AND TO TACKLE DRUG 
 





Nosocomial infections caused by Candida albicans are very common causing 
urinary tract infections like Candiduria[265]. 10 to 15% of nosocomial urinary tract 
infections are reported in hospitalized patients with indwelling devices[266]. Indwelling 
bladder catheters are implicated in ~90% of the 1 million episodes of urinary tract 
infection that occur each year in US hospitals. The last decade has witnessed a rapid 
growth in these infections primarily accounted to resistance developed in microbes to 
commonly used drugs[267]. Candiduria prevalence is associated to immunosuppressive 
therapy, aggressive use of antibiotics, prolonged hospital stays, poor sanitation and 
conditions like diabetes[268].  
Of the 30 million catheters implanted annually in the United States 10 to 30% are 
affected by infections[269]. Candida albicans is responsible for 26% of the urinary tract 
infection in implant recipients[270] and most of these are due to the biofilms formed on 
the surface of catheters which encloses microcolonies of hyphae, pseudo hyphae 
embedded in the protein and polysaccharide matrix yielding to resistance to drugs like 
amphotericin-B and fluconazole rendering them ineffective during the treatment of 
Candiduria[271]. The first step in biofilm formation on a urinary catheter is deposition of
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a conditioning film of host urinary components, including proteins, electrolytes, and other 
organic molecules, which can transform the surface of the urinary catheter and neutralize 
any antiadhesive properties. The chemical nature of the catheter surface is attributed to 
the magnitude of biofilm formation[272].  The architecture of C. albicans biofilm 
depends on the adhering surface indicating that it may depend on highly specific contact-
induced gene expression[273]. 
Encrustation of catheters is a major problem in patients undergoing long term 
bladder catherization[274]. Encrustation is defined as formation of crystalline deposits 
mainly calcium and magnesium phosphates cling to the internal lumen or exposed walls 
of the catheter causing blockage and leading to failure of the implant[275]. Encrustation 
occurs as the result of a 3-step process that incorporates colonization of the catheter with 
bacteria, formation of a biofilm, and crystalline formation[276]. A number of strategies 
have been evaluated but have proved to be ineffective in preventing encrustation. 
Traditionally catheters we made using DEHP and DINP which were recently marked to 
be carcinogenic. Many modern commercial catheter manufacturers like DOVER, 
MEDLINE use silver ions and alloys as surface coating with proven resistant to bacterial 
colonization of the urine this effect only last for the first few days. 
Treatment of encrustation is a painful process which involves frequent catheter 
replacement of acid irrigation through the catheters which digests the blocks[277]. 
Surfaces embedded silver nanoparticles used as coatings on catheters have shown to 
resist bacterial infections but the antimicrobial effect disappeared after a week and is 
predicted to be because of the biofouling of the surface by multiple species of 
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microbes[278]. Silver nanoparticles have also been coated with dopamine on catheter 
materials to create anti-microbial surfaces[279]. 
C. albicans wild type cells have shown to develop 100-fold increase in tolerance 
to fluconazole exposure over that of logarithmic-phase planktonic cells[75]. Fluconazole 
resistance in silicone adhered cells is partially related to surface-induced upregulation of 
drug efflux pumps and is irrespective of biofilm formation[280]. The biofouling activity 
of common fungal commensal Candida albicans involved in more than 50% of catheter 
related urinary tract infection (CRUTI) and approaches to improve antifouling and 
antimicrobial properties are studied.   
Nanostructured surface on the wings of Cicada proved to show the antimicrobial 
potential of NSS against Candida sps. These native nano cone structures were 
biomimetically synthesized by Nowlin et al using polystyrene nanosphere employing a 
nanosphere lithography process by an anisotropic etch using a plasma reactor. Most silver 
nanoparticles synthesis techniques involves solution based processes involving complex 
synthesis condition involving toxic precursor material and harsh biproducts as 
experimental waste[281]. In this study I adopted a green synthesis method of silver 
nanoparticles synthesis described by Chevva et al using a natural biopolymer 
chitosan[282] and filter out the nano particles from formed mixture and use it as coating 
on a commercially available catheter to test the anti-microbial and resistance developing 





4.2 Material and Methods 
4.2.1 Synthesis of Nano Cone Structures Mimicking the NSS of Cicada Wing 
Nanospheres of 400 nm (Polysciences) were resuspended in equal volume of 
water and ethanol and is applied on to glass surface and transferred by inserting the glass 
into a dish with deionized water at a shallow angle. The nanospheres were transferred on 
to a polystyrene surface (petri dish-Fisher scientific) by reversing the previous process. 
Polystyrene surfaces masked with nanospheres were etched using an anisotropic etch in 
South Bay Technology Model PC-2000 Plasma Cleaners in the presence of oxygen at 
100 W forward power and 200mT pressure. 
4.2.2 Green Synthesis of Silver Nanoparticles 
500mg of Chitosan (448869 Sigma-Aldrich) was dissolved in 10ml of deionized 
water with 1% wt of pure glacial acetic acid in the presence of 0.2M sodium chloride in 
5mL solution with continuous stirring on a magnetic stirrer. 5ml of Silver nitrate solution 
in water at 10g/l is added slowly and the mixture is ultra-sonicated overnight. The 
mixture is then centrifuged in an ultra-centrifuge at 14000prm for 30 mins and the 
supernatant with nanoparticles is extracted and used. 
4.2.3 Modification of Catheters for Interaction with C. albicans 
Urinary catheters obtained from Cure medical LLC, California (2024-03-28) were 
used to study the behavior of C. albicans in the catheter environment. Silicone tubing 
manufactured for aquarium use purchased from Walmart was sterilized and used as 
controls. Polyethylene glycol 4000 (81240 Sigma-Aldrich) was sterilized and mixed with 
10% v/v of AgNPs from chitosan mediated AgNP synthesis. The mixture was flowed 
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through the catheters to coat the surface and immobilized by heat treatment at 600C. 
Scanning electron microscopy was performed to see the interaction of C. albicans on 
nano cone surface. 
4.2.4 Interaction of C. albicans on Modified Catheters 
Development of fluconazole resistance in Candida albicans wild type was tested 
by taking C. albicans WT cells from a fresh plate and growing to an OD~0.5 in SDB 
media (dextrose, peptone) diluting them at 1:1 concentration with fresh media and 
inoculating 100 μl of cells on a 10 cm2 etched nano cone surface and 10 cm2 silicone 
surface of the catheter. After 8 hours of interaction on the silicone and synthetic nano 
surface the cells were serial diluted and plated on to an SDB plate with fluconazole drug 
at 0.25 μg/ml, 2 μg/ml,8 μg/ml, 25 μg/ml and 64 μg/ml. The plates were incubated at 
300C overnight and colony forming units were enumerated the next day. 
The antimicrobial activity of the AgNP-PEG modified catheters was tested in 
comparison to control untreated catheters by performing a flow assay of C. albicans wild 
type cells at 10 μl/min through both the tubes of 40 cms length. A serial dilution series 
was performed on the treated cells collected and incubated at 300C overnight and colony 
forming units were enumerated the next day. 
4.3 Results and Discussion 
4.3.1 Synthesis of Nano Cone Structures Mimicking the NSS of Cicada Wing 
Nano structured surfaces created by nano sphere lithography and anisotropic 
plasma etching process were similar in structure and aspect ratio as nano cones on Cicada 








4.3.2 Interaction of WT C. albicans Cells on Bioinspired Nano Cone Surfaces 
Nano cone surfaces on the polystyrene showed a decreased in cell adhesion  
 
compared to the bulk flat surface polystyrene. The imperfections in the nano sphere  
 




micrographs (Figure 4.2) show the adherence and colonization of C. albicans on flat  
 
patches than zones with nano cones etched on them. Though there I found a few ruptured  
 








Silicone surfaces developed fluconazole resistance in wild type Candida albicans 
when the cells adhered to the surface and this effect can be confirmed from the spot plate 
serial dilution studies (figure 4.3)where there was significant growth of C. albicans on 
SBD plate at all dilutions from 10-1 to 10-4  concentrations whereas cells grown on nano 
cone surfaces displayed an inhibition in the growth of cells indicating no drug resistance 




Figure 4.3. Development of fluconazole resistance in Candida albicans wild type. 
Plate 1 shows cells inoculated on silicone tubing Plate 2 cells inoculated on nano 
cone surface. Development of fluconazole resistance can be observed by growth of 
WT C. albicans on 64 μg/ml fluconazole 
 
 
4.3.3 Interaction of C. albicans on Modified Catheters.   
AgNP-chitosan mixture was centrifuged, and the supernatant was aspirated, and 
further analysis was done. DLS analysis from Figure (4.4) of AgNP in ag/chitosan was 






Figure 4.4. DLS Analysis of AgNPs in Ag/Chitosan Solution 
 
 
The results from flow assay showing the anti-microbial efficacy of these catheters 
modified with AgNPs can be read as colony forming units W.T. C. albicans on 
fluconazole plate were enumerated. The acceptable CFU was found at 10-2 concentration 
and number of colonies forming unites were enumerated and tabulated. A significant 





















fluconazole in SDB 
plate 
CFU of C. albicans flowed 
through control catheter tube 
CFU of C. albicans 
flowed through 
modified catheter 
64 μg/ml 87 13 
25 μg/ml 92 11 
8 μg/ml 96 12 
2 μg/ml 102 16 
 
 
Figure 4.5. CFU of serial diluted cells flowed through silicone tubing and AgNP 
modified catheter. Acceptable CFU was observed at 10-2 dilution and number of 










The use of indwelling urinary catheters is becoming more common specially to 
treat organ failure, surgical process and rate of CRUTI is also increasing considerably 
leading to 8% of nosocomial infections. With intensive research in past few years new 
age catheters coated with silver alloys were developed to combat raising infections. 
Silver-coated catheters significantly reduce clinically significant infections such as blood 
steam and kidney infections arising from a UTI[283] by changing the microenvironment 
to prevent biofilm formation[284]. Encrustation of ammonium and phosphate salts and 
their interaction with coated metallic alloys has made encrustation severe causing 
blockage of catheters.  
In this study, I have established PEG-AgNP coatings to urinary catheters which 
had a significant effect on the survival of Candida albicans a major cause for the biofilm 
related infections in medical implants and catheters. The use of silver nanoparticles with 
hydrophilic compounds like polyethylene glycol ensures prevention of encrustation by 
reduced the accumulation of phosphate salts and cumulatively provide antimicrobial 
effect against infectious pathogens[285]. 
The evolution of commonly used fluconazole in C. albicans adhering to silicone 
was demonstrated earlier[75]. To tackle this problem, I study bio inspired nano cone 
structures of the cicada wing created by nanosphere lithography to use as coating on 
medical devices, implants and hospital equipment to reduce the biofouling and also 
provide antimicrobial characteristics to surfaces. Nanosphere lithography gives the 
flexibility to mast any surface with nanostructures without any limitations of size shape 
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and roughness of the material. Nanostructured surfaces are an excellent alternative to 
existing anti-microbial antibiotics and techniques specially proven ability to combat not 






Candida albicans is a common commensal fungus assisting in digestion, nutrient 
absorption and also to maintain the microbial balance in human gut. C. albicans have a 
dimorphic nature and its ability to cause virulence when in the microbiome is disturbed or 
in immunocompromised patients, causes systemic infections with a high mortality rate. 
Though many drugs are available for the treatment of candidiasis, drug resistance in C. 
albicans is a growing concern. In chapter 2, we have established the antimicrobial 
efficacy and antifouling capabilities of nanostructured surface of the Cicada wing 
towards wild type Candida albicans. Timing of rupture of Candida albicans on Cicada 
wing was confirmed at 8 hours. NSS of Cicada have shown to resist microbial adhesion 
creating a model to develop synthetic nano structured surfaces with excellent anti 
biofouling characteristics owing to the surface topology to inhibit biofilm formation. 
These surfaces can have many applications including coatings on catheters and 
indwelling medical devices, dentures and in the areas of sanitation.  
With the increasing resistance in the microbes since the last century and with the 
emergence of super bugs like Candida auris, which is resistant to most available 
antifungal drugs and also has the ability to proliferate outside the human body, the need
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for alternate antimicrobial agents to existing therapies is needed. In chapter 3, I have 
studied the susceptibility of NSS of the Cicada wing on the drug resistant strains of 
Candida albicans and also studied their interactions in terms of adhesion, biofilm 
formation and morphogenesis. Studies confirmed that NSS have a definite effect on the 
adhesion of C. albicans mutants compared to flat surfaces. The mechanism of 
development of resistance to certain drugs also proved to play a role on the fate of C. 
albicans on NSS. Azole resistant C. albicans mutant showed a decrease in cell viability 
on the NSS and also showed the stress induced by these NSS can inhibit the 
morphogenesis from yeast to hyphae. Echinocandin resistant strains which have 
developed resistance by making modification in cell wall against drugs that weakens cell 
wall rigidity showed no significant cell rupture on the NSS and this is predicted to be 
because of a thick cell wall of the mutant strain which protect the cell from NSS assault. 
There was no effect of NSS of Cicada wing on the morphogenesis of these nano cone 
surfaces on the morphogenesis of mutant Candida from yeast to hyphae. These 
experiments confirmed the role of cell wall thickness and rigidity in relation to the 
mechanical strength and stress induced by the nano cone structures. We propose a further 
AFM force spectroscopy study to measure the mechanical modulus of cell wall of various 
mutant strains of Candida albicans to create surfaces of desired aspect ratio and strength 
to use as coatings for various biomedical applications.  
Biofilms associated to Candida species are a great health concern and are 
responsible for about 60% of nosocomial infections. Biofilms produced by drug resistant 
strains are difficult to treat and exponentially increase health hazards in implant recipients 
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by housing other deadly microbes like MRSA. We have observed significant decrease in 
biofilm formation in all the three stages i.e., early, matured and late phases on the NSS of   
Cicada wing compared to the flat surfaces. This is primarily attributed to a decreased 
adhesion, cell rupture on NSS and also inhibition of hyphal formation which binds the 
biofilm colony together. This effect boosts the idea of using nanostructured coatings in 
the areas of sanitation specially to reduce bacterial and fungal infections. 
Use of catheters is becoming more common in modern day medicine in people 
suffering from cardiac diseases, organ removal due to cancer, paralysis of organ systems 
and in most indwelling medical devices. Urinary catheters traditionally are simple sterile 
silicone tubing which are used mostly in paralyzed or mentally/physically challenged 
patients. Candida albicans is related to 50% of CRUTI and a need to tackle this is 
increasing rapidly. Though many commercial companies have used metal ions and alloys 
to coat catheters with silver to use its innate antimicrobial property for microbial growth 
inhibition, the problem of encrustation where the catheters are blocked by deposited salts 
is persistent. We demonstrate an AgNP dispersed in PEG as coatings to commercially 
available urinary catheters to solve the problem of biofouling and also encrustation. A 
decrease in cell viability on fluconazole-SDB plate was observed confirming the action of 
AgNP-PEG coating as an effective antifouling and antimicrobial agent. 
Fluconazole is the most commonly used over the counter drug for fungal 
infections and increase in resistance will make it ineffective. While most catheters are 
made of silicone, the evolution of silicone adhered Candida cells by 100-fold to 
fluconazole was demonstrated earlier. In chapter 3 we demonstrate the effect of
93 
 
synthetically created nano cone surfaces by using nano sphere lithography to inhibit the 
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